Achieve Life Sciences (ACHV) Q2 2026 earnings — TrendMatrix coverage

Reported EPS

—

Estimate

-$0.16

Surprise

—

Score today

5.3/10

Revenue for this quarter isn’t shown: the reported figure hasn’t cleared TrendMatrix’s freshness and sanity checks yet, and consensus revenue isn’t tracked. EPS above is the available figure.

TrendMatrix currently rates ACHV Sell at 5.3/10; no pre/post engine snapshot brackets this report.

1 of the last 4 quarters beat the estimate. Next scheduled report: 2026-11-05.

This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.

Current price

$7.56

Price target

$12.03

Stop

$6.90

Upside to target

+59.1%

Reward-to-risk

6.1:1

Model outputs from TrendMatrix’s engine as of 2026-09-17 — shown for context, not personalized investment advice.

Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.

Industry

Biotechnology

Market cap

$753.2M

P/E (fwd)

-11.5

52-week range

$2.62–$8.64

Off 52-week high

12.5%

RSI (14)

36

Volume vs avg

1.17×

Score today

5.3/10